GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD) from its SEC filings: 2025 revenue $29.4 billion (+2% vs the year before), net margin 29%, free cash flow $9.5 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $29.4 billion |
| Revenue growth | +2% |
| Net income | $8.5 billion |
| Net margin | 28.9% |
| Free cash flow | $9.5 billion |
| Diluted EPS | $6.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $5.4 billion |
| Long-term debt | $23.8 billion |
| Share count, 1 year | -0% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.